TY - JOUR
T1 - Synergy of molecular targeted approaches and immunotherapy in melanoma
T2 - Preclinical basis and clinical perspectives
AU - Sanlorenzo, Martina
AU - Vujic, Igor
AU - Moy, Adrian
AU - Quaglino, Pietro
AU - Fierro, Maria Teresa
AU - Gammaitoni, Loretta
AU - Carnevale-Schianca, Fabrizio
AU - Aglietta, Massimo
AU - Sangiolo, Dario
PY - 2015/10/3
Y1 - 2015/10/3
N2 - Introduction: Targeted therapy and immunotherapies are the novel pharmacologic treatment strategies for metastatic melanoma. BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response. The aim of this work is to discuss the rationale, evidence and perspectives of approaches combining target and immunotherapy against melanoma.Areas covered: We first review the effects of BRAF and MEK inhibitors on melanoma cells and on the different components of the immune system. Afterwards, we summarize the results of the preclinical and clinical studies that have combined targeted therapy and immunotherapy for the treatment of melanoma.Expert opinion: Clinical applications of immunotherapy strategies have recently changed the therapeutic mainstay for metastatic melanoma. Biologic and initial preclinical data support their integration with innovative molecular targeted therapies, opening enormous perspectives for researchers in the effort of finding a definitive cure. Main open challenges are the definition of reliable research models, assessment of effective schedules, safety issues and designing of personalized approaches.
AB - Introduction: Targeted therapy and immunotherapies are the novel pharmacologic treatment strategies for metastatic melanoma. BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response. The aim of this work is to discuss the rationale, evidence and perspectives of approaches combining target and immunotherapy against melanoma.Areas covered: We first review the effects of BRAF and MEK inhibitors on melanoma cells and on the different components of the immune system. Afterwards, we summarize the results of the preclinical and clinical studies that have combined targeted therapy and immunotherapy for the treatment of melanoma.Expert opinion: Clinical applications of immunotherapy strategies have recently changed the therapeutic mainstay for metastatic melanoma. Biologic and initial preclinical data support their integration with innovative molecular targeted therapies, opening enormous perspectives for researchers in the effort of finding a definitive cure. Main open challenges are the definition of reliable research models, assessment of effective schedules, safety issues and designing of personalized approaches.
KW - BRAF inhibitors
KW - immunotherapy
KW - melanoma
KW - targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84942054101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942054101&partnerID=8YFLogxK
U2 - 10.1517/14712598.2015.1069272
DO - 10.1517/14712598.2015.1069272
M3 - Article
C2 - 26206099
AN - SCOPUS:84942054101
VL - 15
SP - 1491
EP - 1500
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - 10
ER -